Literature DB >> 32905234

Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review.

I S Voruganti1, E Donovan1,2, C Walker-Dilks3, A Swaminath4,5.   

Abstract

Background: Radiation-induced chest wall pain (cwp) and rib fracture (rf) are late adverse effects after stereotactic body radiation therapy (sbrt) for stage i non-small-cell lung cancer (nsclc); however, the literature about their incidence and risk factors shows variability. We performed a systematic review to determine the pooled incidence of cwp and rf in the relevant population.
Methods: A literature search using the prisma (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines considered English publications in medline and embase from January 1996 to August 2017. Abstracts were screened, followed by full-text review and data extraction.
Results: The database searches identified 547 records. Twenty-eight publications comprising 3892 patients met the inclusion criteria. Median reported ages and follow-up durations fell into the ranges 67-82 years and 12-84 months. Prescriptions fell into the range of 40-70 Gy in 3-10 fractions. Despite study heterogeneity, the pooled incidences of cwp and rf were estimated to be 8.94% and 5.27% respectively. Nineteen studies reported cwp grade: 58 of 308 patients (18.8%) experienced grades 3-4 cwp (no grade 5 events reported). Thirteen studies reported rf grade: grades 3-4 rf were observed in 9 of 113 patients (7.96%). A high chest wall V 30 was an important predictor of cwp and rf. Conclusions: In patients with stage i nsclc, rates of cwp and rf after sbrt are low; however, tumour location, accurate toxicity reporting, and dose-fractionation schemes might alter those rates. Prospective correlation with dosimetry and quality of life assessment will further improve the understanding of cwp and rf after sbrt. 2020 Multimed Inc.

Entities:  

Keywords:  Chest wall pain; non-small-cell lung cancer; rib fracture; stereotactic body radiation therapy; systematic reviews

Mesh:

Year:  2020        PMID: 32905234      PMCID: PMC7467794          DOI: 10.3747/co.27.5959

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  43 in total

Review 1.  Persistent postsurgical pain: risk factors and prevention.

Authors:  Henrik Kehlet; Troels S Jensen; Clifford J Woolf
Journal:  Lancet       Date:  2006-05-13       Impact factor: 79.321

2.  Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship.

Authors:  Kaori Asai; Yoshiyuki Shioyama; Katsumasa Nakamura; Tomonari Sasaki; Saiji Ohga; Takeshi Nonoshita; Tadamasa Yoshitake; Kayoko Ohnishi; Kotaro Terashima; Keiji Matsumoto; Hideki Hirata; Hiroshi Honda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-23       Impact factor: 7.038

3.  Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.

Authors:  Anand Swaminath; Marcin Wierzbicki; Sameer Parpia; James R Wright; Theodoros K Tsakiridis; Gordon S Okawara; Vijayananda Kundapur; Alexis Bujold; Naseer Ahmed; Khalid Hirmiz; Elizabeth Kurien; Edith Filion; Zsolt Gabos; Sergio Faria; Alexander V Louie; Timothy Owen; Elaine Wai; Kevin Ramchandar; Elisa K Chan; Jim Julian; Kathryn Cline; Timothy J Whelan
Journal:  Clin Lung Cancer       Date:  2016-10-03       Impact factor: 4.785

4.  Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller.

Authors:  Satoru Ochiai; Koichiro Yamakado; Hiroshi Kodama; Yoshihito Nomoto; Noriko Ii; Haruyuki Takaki; Hajime Sakuma
Journal:  Int J Clin Oncol       Date:  2014-08-19       Impact factor: 3.402

5.  Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.

Authors:  Cornelis J A Haasbeek; Frank J Lagerwaard; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

6.  Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Bronno van der Holt; Cora Braat; Robertus J van Klaveren; Peter M Pattynama; Peter C Levendag; Joost J Nuyttens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-26       Impact factor: 7.038

7.  Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

Authors:  Joe Y Chang; Qiao-Qiao Li; Qing-Yong Xu; Pamela K Allen; Neal Rebueno; Daniel R Gomez; Peter Balter; Ritsuko Komaki; Reza Mehran; Stephen G Swisher; Jack A Roth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

8.  A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours.

Authors:  Jan Seppala; Sami Suilamo; Jarmo Kulmala; Pekka Mali; Heikki Minn
Journal:  Radiat Oncol       Date:  2012-05-31       Impact factor: 3.481

9.  Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy.

Authors:  Mojgan Taremi; Andrew Hope; Patricia Lindsay; Max Dahele; Sharon Fung; Thomas G Purdie; David Jaffray; Laura Dawson; Andrea Bezjak
Journal:  Radiat Oncol       Date:  2012-09-17       Impact factor: 3.481

10.  Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry.

Authors:  Thibaud P Coroller; Raymond H Mak; John H Lewis; Elizabeth H Baldini; Aileen B Chen; Yolonda L Colson; Fred L Hacker; Gretchen Hermann; David Kozono; Edward Mannarino; Christina Molodowitch; Jon O Wee; David J Sher; Joseph H Killoran
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.